

METRO DRUG COALITION, INC.
FINANCIAL STATEMENTS
WITH SUPPLEMENTARY INFORMATION
For the Year Ended September 30, 2024
and
INDEPENDENT AUDITOR'S REPORT

METRO DRUG COALITION, INC.
FINANCIAL STATEMENTS
WITH SUPPLEMENTARY INFORMATION
For the Year Ended September 30, 2024

TABLE OF CONTENTS

	<u>Page</u>
Introductory Section:	
List of Principal Officials	1
Financial Statements:	
Independent Auditor's Report	2 – 4
Statement of Financial Position	5
Statement of Activities	6
Statement of Functional Expenses	7
Statement of Cash Flows	8
Notes to Financial Statements	9 – 17
Supplementary Information:	
Schedule of Expenditures of Federal and State Awards	18 – 19
Notes to the Schedule of Expenditures of Federal and State Awards	20
Internal Control and Compliance Section:	
Independent Auditor's Report on Internal Control over Financial Reporting and on Compliance and Other Matters Based on an Audit of Financial Statements Performed in Accordance with <i>Government Auditing Standards</i>	21 – 22
Independent Auditor's Report on Compliance for Each Major Program and on Internal Control over Compliance Required by the Uniform Guidance and Accompanying Schedule of Findings and Questioned Costs	23 – 27
Summary Schedule of Prior Audit Findings	28
Corrective Action Plan	29

METRO DRUG COALITION, INC.

LIST OF PRINCIPAL OFFICIALS

September 30, 2024

Executive Committee Members

Barbara Shipley, President
Elizabeth L. Sherrod, Vice President
Dan F. Sherrod, Jr., Treasurer
Maha Krishnamurthy, Immediate Past President

Executive Committee – At Large

Randall E. Nichols
General Charmé Allen
Samuel French, CPA
Jim Lapinska

Board At Large Members

Tanisha Baker
Richie Beeler
Michele Carringer
Betsy Henderson
Honorable Tim Irwin
Mayor Glenn Jacobs
Mayor Indya Kincannon
Eric Lutton
George M. Massengill
Chuck Morris
Paul Noel
Kevin Parton
Jon Rysewyk
Seema Singh
April Snell
Sheriff Tom Spangler
Charles W. Swanson
Janet Testerman
Zach Wishart

Advisory Board Members

Erik Ainge
John W. Gill, Jr.
Otto T. Wright
Donald B. Wake, CPCU

BROWN JAKE & McDANIEL, PC

CERTIFIED PUBLIC ACCOUNTANTS
 2607 KINGSTON PIKE, SUITE 110
 KNOXVILLE, TENNESSEE 37920-3336
 865/637-8600 • fax: 865/637-8601
 www.bjmpc.com

JOE L. BROWN, CPA, CGFM, CGMA
 FRANK D. McDANIEL, CPA, CGFM, CGMA
 TERRY L. MOATS, CPA, CGFM, CGMA
 JAMES E. BOOHER, CPA, CGMA
 HALEY S. SLAGLE, CPA, CGMA

MEMBERS
 AMERICAN INSTITUTE OF
 CERTIFIED PUBLIC ACCOUNTANTS

Independent Auditor's Report

Board of Directors
 Metro Drug Coalition, Inc.
 Knoxville, Tennessee

Report on the Audit of the Financial Statements

Opinion

We have audited the accompanying financial statements of the Metro Drug Coalition, Inc. (a nonprofit organization), which comprise the statement of financial position as of September 30, 2024, and the related statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the financial statements.

In our opinion, the financial statements present fairly, in all material respects, the financial position of Metro Drug Coalition, Inc. as of September 30, 2024, and the changes in its net assets and its cash flows for the year then ended in accordance with accounting principles generally accepted in the United States of America

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of Metro Drug Coalition, Inc. and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Financial Statements

Management is responsible for the preparation and fair presentation of the financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about Metro Drug Coalition, Inc.'s ability to continue as a going concern within one year after the date that the financial statements are ready to be issued.

Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the financial statements.

In performing an audit in accordance with generally accepted auditing standards and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of Metro Drug Coalition, Inc.'s internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about Metro Drug Coalition, Inc.'s ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplementary Information

Our audit was conducted for the purpose of forming an opinion on the financial statements as a whole. The accompanying schedule of expenditures of federal and state awards, as required by Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Costs Principles, and Audit Requirements for Federal Awards*, is presented for purposes of additional analysis and is not a required part of the financial statements. Such information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the financial statements. The information has been subjected to the auditing procedures applied in the audit of the financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the financial statements or to the financial statements themselves, and other additional procedures in accordance with auditing standards generally accepted in the United States of America. In our opinion, the schedule of expenditures of federal and state awards is fairly stated, in all material respects, in relation to the financial statements as a whole.

Other Information

Management is responsible for the other information included in the annual report. The other information comprises the introductory section but does not include the basic financial statements and our auditor's report thereon. Our opinion on the basic financial statements do not cover the other information, and we do not express an opinion or any form of assurance thereon.

In connection with our audit of the basic financial statements, our responsibility is to read the other information and consider whether a material inconsistency exists between the other information and the basic financial statements, or the other information otherwise appears to be materially misstated. If, based on the work performed, we conclude that an uncorrected material misstatement of the other information exists, we are required to describe it in our report.

Other Reporting Required by Government Auditing Standards

In accordance with *Government Auditing Standards*, we have also issued our report dated August 13, 2025 on our consideration of Metro Drug Coalition, Inc.'s internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of Metro Drug Coalition, Inc.'s internal control over financial reporting or on compliance. In accordance with the Uniform Guidance, we have also issued our report dated August 13, 2025 on our consideration of the Coalition's internal control over major programs and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering Metro Drug Coalition, Inc.'s internal control over financial reporting and compliance.

Brown Lake + McDaniel, PC

Knoxville, Tennessee
August 13, 2025

METRO DRUG COALITION, INC.
STATEMENT OF FINANCIAL POSITION
September 30, 2024

ASSETS

Current assets:	
Cash	\$ 173,101
Grants receivable	274,987
Prepaid expense	6,276
Investments	372,698
Security deposit	<u>1,050</u>
Total current assets	<u>828,112</u>
Property and equipment:	
Building and improvements	900,000
Leasehold improvements	3,628,720
Office furniture and equipment	<u>62,145</u>
	4,590,865
Less accumulated depreciation	<u>163,354</u>
Net property and equipment	<u>4,427,511</u>
Total assets	<u><u>\$ 5,255,623</u></u>

LIABILITIES AND NET POSITION

Current liabilities:	
Accounts payable	\$ 104,015
Current due on line of credit	66,276
Accrued liabilities	<u>46,053</u>
Total current liabilities	<u>216,344</u>
Noncurrent liabilities:	
Line of credit	<u>222,968</u>
Total noncurrent liabilities	<u>222,968</u>
Net position:	
Without donor restrictions	4,816,311
With donor restrictions	<u>-</u>
Total net position	<u>4,816,311</u>
Total liabilities and net position	<u><u>\$ 5,255,623</u></u>

The accompanying notes are an integral
part of these financial statements.

METRO DRUG COALITION, INC.

STATEMENT OF ACTIVITIES

For the Year Ended September 30, 2024

	Without Donor Restrictions	With Donor Restrictions	Total
Support and revenue:			
Revenues, gains and other support:			
Federal and state grants	\$ 1,518,712	\$ -	\$ 1,518,712
Local government grants	91,660	-	91,660
Contributions and support	321,838	130,500	452,338
Gifts in kind	5,796	-	5,796
Interest and dividend income	7,982	-	7,982
Investment return, net	64,575	-	64,575
Sales of merchandise, net of direct costs \$29,939	(22,838)	-	(22,838)
Special event	210,005	-	210,005
Miscellaneous Income	134,826	-	134,826
Net assets released from restrictions:			
Satisfaction of program service or asset acquisition restrictions	130,500	(130,500)	-
Total revenues, gains and other support	<u>2,463,056</u>	<u>-</u>	<u>2,463,056</u>
Expenses:			
Program services	1,890,983	-	1,890,983
Support services:			
Management and general	235,700	-	235,700
Fundraising	212,176	-	212,176
Total expenses	<u>2,338,859</u>	<u>-</u>	<u>2,338,859</u>
Change in net position	124,197	-	124,197
Net position, beginning of year	<u>4,692,114</u>	<u>-</u>	<u>4,692,114</u>
Net position, end of year	<u>\$ 4,816,311</u>	<u>\$ -</u>	<u>\$ 4,816,311</u>

The accompanying notes are an integral part of these financial statements.

METRO DRUG COALITION, INC.
STATEMENT OF FUNCTIONAL EXPENSES
For the Year Ended September 30, 2024

	Support Services			Total
	Program Services	Management and General	Fundraising	
Salaries and benefits	\$ 690,814	\$ 140,997	\$ 112,111	\$ 943,922
Professional services	27,477	16,820	3,551	47,848
Contractual expenses	594,144	4,000	-	598,144
Information technology	13,574	1,868	6,739	22,181
Supplies	131,667	10,521	1,815	144,003
Telephone	8,699	613	902	10,214
Printing and postage	4,443	2,402	270	7,115
Building maintenance	24,262	-	2,817	27,079
Utilities	16,992	962	447	18,401
Equipment rental and maintenance	7,351	2,529	486	10,366
Travel	30,627	1,553	471	32,651
Meeting/training expenses	9,033	4,152	600	13,785
Insurance	23,412	898	2,773	27,083
Membership dues and professional development	24,533	2,937	640	28,110
Community awareness	94,403	2,130	-	96,533
Special event expense	-	-	60,178	60,178
Program events	17,395	-	-	17,395
Taxes and licenses	12,618	8,779	40	21,437
Interest expense	-	10,642	-	10,642
Miscellaneous	83	6,192	631	6,906
Recovery payments expense	68,400	-	-	68,400
	<u>1,799,927</u>	<u>217,995</u>	<u>194,471</u>	<u>2,212,393</u>
Total expenses before depreciation				
Depreciation expense	91,056	17,705	17,705	126,466
Total expenses	<u>1,890,983</u>	<u>235,700</u>	<u>212,176</u>	<u>2,338,859</u>

The accompanying notes are an integral
part of these financial statements.

METRO DRUG COALITION, INC.

STATEMENT OF CASH FLOWS

For the Year Ended September 30, 2024

Cash flows from operating activities:	
Change in net position	\$ 124,197
Adjustments to reconcile change in net position to net cash provided by operating activities:	
Net realized and unrealized (gains) and losses on investments	57,162
Depreciation	126,466
(Increase) decrease in assets:	
Grants receivable	45,783
Prepaid expense	13,703
Increase (decrease) in liabilities:	
Accounts payable	(65,856)
Accrued liabilities	14,964
Net cash provided by operating activities	<u>316,419</u>
Cash flows from investing activities:	
Acquisition and construction of capital assets	(77,977)
Proceeds of investments	146,677
Purchases of investments	<u>(255,750)</u>
Net cash used by investing activities	<u>(187,050)</u>
Cash flows from financing activities:	
Principal paid on line of credit	<u>(75,732)</u>
Net cash used by financing activities	<u>(75,732)</u>
Increase in cash and cash equivalents	53,637
Cash and cash equivalents, beginning	<u>119,464</u>
Cash and cash equivalents, ending	<u>\$ 173,101</u>
Cash and cash equivalents - unrestricted	\$ 173,101
Cash and cash equivalents - restricted	<u>-</u>
	<u>\$ 173,101</u>
Supplemental disclosures of cash flow information:	
Cash paid during the year for:	
Interest	\$ 10,642

6

The accompanying notes are an integral part of these financial statements.

METRO DRUG COALITION, INC.
NOTES TO FINANCIAL STATEMENTS

September 30, 2024

1. Organization and Mission

The Metro Drug Coalition, Inc. ("MDC" or the "Coalition") was chartered in 1986 as a corporation formed by a joint resolution by the City of Knoxville (the "City") and Knox County. The mission of the Coalition is to improve the health of the greater Knoxville community by reducing the use/misuse of alcohol and other substances through prevention, harm reduction, and recovery support.

2. Summary of Significant Accounting Policies

Method of Accounting

The financial statements of the Coalition are prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.

Tax Status

The Coalition is classified as an organization exempt from income tax under Internal Revenue Code Section 501(c)(3) as other than a private foundation and, accordingly, no provision for income taxes has been included in the accompanying financial statements.

The Coalition follows the provisions of Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) 740-10-25. The Coalition does not believe there are any material uncertain tax positions and, accordingly, it will not recognize any liability for unrecognized tax benefits. For the year ended September 30, 2024, there were no interest or penalties recorded or included in its financial statements.

The Coalition's Form 990, *Return of Organization Exempt from Income Tax*, for the years ended 2021 through 2024 are subject to examination by the IRS, generally for three years after they were filed.

Basis of Presentation

The Coalition prepares financial statements in accordance with FASB Accounting Standards Codification (ASC) 958-205 and subsections. Under this standard, the Coalition is required to report information regarding its financial position and activities according to two classes of net assets: net assets without donor restrictions and net assets with donor restrictions.

Net Assets Without Donor Restrictions: Net assets that are not subject to or are no longer subject to donor-imposed stipulations.

Net Assets With Donor Restrictions: Net assets whose use is limited by donor-imposed time and/or purpose restrictions.

Donor Restricted Contributions

Support that is restricted by the donor is reported as an increase in net assets without donor restrictions if the restriction expires in the reporting period in which the support is recognized. All other donor-restricted support is reported as an increase in net assets with donor restrictions. When a restriction expires, net assets with donor restrictions are reclassified to net assets without donor restrictions.

METRO DRUG COALITION, INC.
NOTES TO FINANCIAL STATEMENTS
(Continued)

2. Summary of Significant Accounting Policies (Continued)

Cash and Cash Equivalents

For purposes of the statement of cash flows, the Coalition considers all highly liquid debt instruments purchased with a maturity date of three months or less to be cash equivalents.

Receivables and Revenue Recognition

For grant awards that are on a cost reimbursement basis, revenue is recognized to the extent grant expenses have been incurred. Revenue from contributions and other grant awards is recorded when cash is received or an unconditional promise to give is made.

Investments and Fair Value Measurements

The Coalition follows FASB ASC 820 which defines fair value, establishes a framework for measuring fair value, establishes a fair value hierarchy based on the quality of inputs used to measure fair value, and requires enhanced disclosures about fair value measurements. Fair value is the amount that would be received to sell an asset, or paid to transfer a liability, in an orderly transaction between market participants at the measurement date (i.e., the exit price).

Certificates of deposit are reported at fair market value based on the account balance at the financial institution on the last business day of the year.

Investments for which observable market prices in active markets do not exist are reported at fair value, as determined in good faith by management.

Realized gains and losses are determined by comparison of asset average cost, or fair market value at the date of donation or market value at the beginning of the year, to net proceeds received at the time of disposal. Unrealized gains and losses are determined by the difference between market values at the beginning and end of the year. These amounts are reflected in the financial statements as net realized and unrealized gains (losses) on investments.

See Note 5, Investments, Fair Value Measurements and Endowments, for further discussion relating to ASC 820-10 and the Coalition's investments.

The Coalition's policy regarding investment income and realized and unrealized gains and losses for net assets with donor-imposed restrictions is to record such revenues as unrestricted support to the extent that restrictions are met in the same reporting period.

Investments in marketable securities with readily determinable fair values and all investments in debt securities are valued at their fair values in the statement of financial position. Unrealized gains and losses are included in the change in net assets.

METRO DRUG COALITION, INC.
 NOTES TO FINANCIAL STATEMENTS
 (Continued)

2. Summary of Significant Accounting Policies (Continued)

Property and Equipment

Property and equipment are carried at cost. When assets are retired or otherwise disposed of, the cost and related accumulated depreciation are removed from the accounts, and any resulting gain or loss is reflected in income for the period. The cost of maintenance and repairs is charged to income as incurred; significant renewals and betterments are capitalized. Deduction is made for retirements resulting from renewals and betterments. The Coalition's capitalization threshold is \$5,000.

Land and improvements and construction/retirement in progress are not depreciated. The other property, equipment, and leasehold improvements are depreciated using the straight-line method over the following estimated useful lives:

<u>Description</u>	<u>Estimated Useful Lives</u>
Buildings and improvements	40 years
Furniture and equipment	5 - 10 years

Net Asset Classification

Net assets with donor restrictions consist of donor restricted contributions. When donor restrictions expire, that is, when a stipulated time restriction ends or a purpose restriction is fulfilled, net assets with donor restrictions are reclassified to net assets without donor restrictions and reported in the statement of activities as net assets without donor restrictions. Grants and donor restricted gifts are classified as net assets without donor-imposed restrictions if the restriction expires in the same fiscal year. See Note 7 for assets with donor-imposed restrictions.

Functional Allocation of Expenses

Certain expenses of the Coalition have been allocated between program and supporting services. These allocations are determined by the Coalition's management either by specific identification, percentage proration of personnel, or other specific costs.

Donated Materials, Facilities and Services

Donations of non-cash supplies and materials, rent and utilities are recorded at their estimated fair values at the date of donation.

METRO DRUG COALITION, INC.
NOTES TO FINANCIAL STATEMENTS
(Continued)

2. Summary of Significant Accounting Policies (Continued)

Donated Materials, Facilities and Services (Continued)

Donated services by individuals are recognized as contributions in accordance with FASB ASC 958, if the services create or enhance non-financial assets or require specialized skills and would otherwise be purchased by the Coalition. Amounts are reported in the financial statements for voluntary donations of services when those services create or enhance non-financial assets or require specialized skills provided by the donation. There were \$5,796 in donated accounting services in 2024. Numerous volunteers, including members of the Coalition's Board of Directors, have donated significant amounts of their time to the Coalition's program services and to the maintenance of its facilities that are not recognized as contributions in the financial statements since the criteria for FASB ASC 958 are not met.

Subsequent Events

In preparation of the accompanying financial statements, management has evaluated subsequent events that have occurred since the statement of financial position date through August 13, 2025, the date the financial statements were available for issuance.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect certain amounts and disclosures. Accordingly, actual results could differ from those estimates.

Endowment, Investments and Spending Policies

East Tennessee Foundation Endowment

MDC has adopted the investment and spending policies of the East Tennessee Foundation "The Foundation" for endowment assets that attempt to provide a predictable stream of funding to programs supported by its endowment funds while seeking to maintain the purchasing power of the endowment assets. The Foundation's spending and investment policies work together to achieve this objective. To achieve the investment goal, the Foundation's Investment Committee establishes investment objectives and strategies of equity, fixed income, cash, and non-traditional investments within prudent risk parameters.

METRO DRUG COALITION, INC.
NOTES TO FINANCIAL STATEMENTS
(Continued)

2. Summary of Significant Accounting Policies (Continued)

Endowment, Investments and Spending Policies (Continued)

East Tennessee Foundation Endowment (Continued)

The objective is to achieve a total annual return, measured on a five-year moving average basis equal to the spending rate as determined by the Foundation plus the inflation rate. The Foundation relies on a total return strategy in which investment returns are achieved through both capital appreciation (realized and unrealized) and current yield (interest and dividends). The spending policy calculates the amount of money annually distributed from the Foundations' various endowed funds for grant making. The Foundation adopted a 4½% annual spending level for grant distributions to be calculated on a rolling average of twelve quarters of ending market values. This is consistent with the Foundation's objective to maintain the purchasing power of endowment assets as well as to provide additional real growth through new gifts and investment return.

The principal of the endowment is permanent and irrevocable and cannot be spent. At the discretion of the board, up to 100% of the yearly total return may be used for program and agency expenses unless restricted for a specific purpose by the donors.

Other Investment Funds

The Coalition has also adopted investment policies for short-term and long-term reserve funds.

The purpose of the short-term reserve fund is to meet unanticipated expenses of the Coalition and to improve returns on the funds held for expenditure for up to five years. The objectives are preservation of capital, liquidity, and to optimize investment return.

The allowable investments for the short-term reserve funds are interest bearing savings or checking accounts, certificate of deposits, money market funds, mutual funds that invest in direct obligations of the U.S. Government, and direct obligations of the U.S. Government. All of these will have a weighted average maturity of three years or less. The maximum maturity will be five years.

The purpose of the long-term reserve fund is to provide secure long-term funding for the mission of MDC. Expenditure of the principal is board designated unless otherwise designated by the donors in part or in whole. Also, at the discretion of the board, up to 100% of the yearly total return may be utilized for program and agency expenses unless restricted for specific purposes by the donors.

The objectives of the long-term reserve fund are to emphasize the long-term growth of principal while avoiding excessive risk and to achieve returns in excess of the rate of inflation plus spending over the investment time horizon in order to preserve purchase power of agency and trust assets.

METRO DRUG COALITION, INC.
NOTES TO FINANCIAL STATEMENTS
(Continued)

2. Summary of Significant Accounting Policies (Continued)

Endowment, Investments and Spending Policies (Continued)

Other Investment Funds (Continued)

MDC has adopted the asset allocation guidelines as equities at 30% up to 70%, fixed income at 30% up to 70%, and cash equivalent at 0% up to 20%. The allowable investments for cash equivalents are treasury bills, money market funds, certificates of deposits, etc. Allowable fixed income securities will be U.S. Government and Agency securities, corporate notes and bonds with an investment grade of at least BBB, mortgage backed bonds, and preferred stock. Allowable equity securities are common stocks, convertible notes and bonds, convertible preferred stocks, and American Depository Receipts of non-US companies. Allowable long-term investments also include mutual funds that invest in the allowable securities of the investment policy.

3. Employee Benefit Plan

The Coalition has a contributory retirement plan for all employees working over 30 hours per week. Participants are required to contribute a minimum of 6% of their compensation, as defined, to the Plan. The Coalition matches participant contributions up to 6% of the participants' compensation to the Plan. The Coalition contributed \$43,196 in 2024 to the Plan.

4. Concentration of Credit Risk

As of September 30, 2024, MDC's cash on deposit with financial institutions did not exceed the Federal Deposit Insurance Corporation ("FDIC") insurance coverage.

5. Investments, Fair Value Measurements and Endowments

FASB ASC 820 establishes a framework for measuring fair value and a three-level hierarchy for fair value measurements based upon the transparency of inputs to the valuation of an asset or liability. The classification of assets and liabilities within the hierarchy is based on whether the inputs to the valuation methodology used for measurement are observable or unobservable. Observable inputs reflect market-derived or market-based information obtained from independent sources while unobservable inputs reflect estimates about market data based on the best information available in the circumstances.

The fair value hierarchy prioritizes the inputs to valuation techniques used to measure fair value into three broad levels:

Level 1 – Inputs are quoted prices in active markets for identical investments as of the reporting date. Investments in this category include certificates of deposit, equity securities and mutual funds.

Level 2 – Inputs are observable for the investments, directly or indirectly, as of the reporting date. Fair value is determined through the use of models or other valuation methodologies. Investments which are generally included in this category include corporate bonds and loans, less liquid and restricted equity securities, and certain over-the counter derivatives.

METRO DRUG COALITION, INC.
NOTES TO FINANCIAL STATEMENTS
(Continued)

5. Investments, Fair Value Measurements and Endowments (Continued)

Level 3 – Inputs are unobservable and reflect assumptions on the part of the reporting entity. The investment that is included in this category is a limited partnership interest in real estate.

The table that follows sets forth information about the levels within the fair value hierarchy at which MDC's investments are measured at September 30, 2024:

	Level 1	Level 2	Level 3	Total
Investments	\$ 372,698	\$ -	\$ -	\$ 372,698

At September 30, 2024, investments consisted of the following:

Investments Without Donor Restrictions

MDC Reserve Funds

The investments of The Trust Company Reserve Funds are held in trust by The Trust Company and can be cash or non-cash items with a current total value:

	<u>Cost</u>	<u>Fair Value</u>
Cash and cash equivalents	\$ 22,857	\$ 22,857
Domestic equity	77,760	139,759
International equity	59,288	70,169
Accrued income	203	203
Fixed income	44,147	43,903
REITs	8,660	11,143
Total	\$ 212,915	\$ 288,034

East Tennessee Foundation Endowment Fund

The investments of the East Tennessee Foundation Endowment Fund are held in trust by East Tennessee Foundation and can be cash or non-cash items with a current total value:

Total Investments

	<u>Fair Value</u>
Total Investments held by the East Tennessee Foundation	\$ 84,664

METRO DRUG COALITION, INC.
NOTES TO FINANCIAL STATEMENTS
(Continued)

6. Endowment Fund

Endowment net assets without donor restrictions compositions as of September 30, 2024 are as follows:

	2024
	Without Donor Restriction
East Tennessee Foundation	\$ 84,664
Total Endowment Funds	\$ 84,664

Changes in endowment net assets for the year ended September 30, 2024 are as follows:

	Without Donor Restrictions	Total Net Assets
Endowment net assets at September 30, 2023	\$ 71,244	\$ 71,244
Contributions	-	-
Investment income	1,000	1,000
Net realized and unrealized gains (losses) on investments	13,645	13,645
Administrative and investment fees	(1,225)	(1,225)
Endowment net assets at September 30, 2024	\$ 84,664	\$ 84,664

7. Net Assets with Donor Restrictions

The Gateway is an initiative to establish a recovery community center anchored in the heart of the Knoxville community providing services such as: recovery coaching, recovery meetings of various types, art therapy, music therapy, connecting to jobs, housing and financial institutions and others designed to assist in restoring the lives of individuals and families affected by substance misuse. As of September 30, 2024, the Coalition had released all of its restricted net assets.

METRO DRUG COALITION, INC.
NOTES TO FINANCIAL STATEMENTS
(Continued)

8. Liquidity and Availability of Financial Assets

The following reflects Metro Drug Coalition's financial assets as of September 30, 2024, reduced by amounts not available for general use because of contractual or donor-imposed restrictions or governing board designations within one year of the balance sheet date:

Cash and cash equivalents	\$	173,101
Grants receivable		274,987
Investments		372,698
Total financial assets		820,786
Less those unavailable for general expenditures within one year due to:		
Donor-imposed restrictions		-
Financial assets available to meet cash needs for general expenditures within one year	\$	820,786

As of September 30, 2024, the Coalition had no financial assets subject to donor or other contractual restrictions or governing board designations that make them unavailable for general expenditure within one year of the balance sheet date. Metro Drug Coalition maintains financial assets, which consist of cash, receivables, and investments to meet normal operating expenses within one year which, on average, are \$323,949. Metro Drug Coalition is developing a liquidity management policy to structure its financial assets to be available as its general expenditures, liabilities, and other obligations come due.

9. Line of Credit

The Coalition has an available line of credit of \$1,300,000 with a bank that is due on March 18, 2026. Principal and interest are payable monthly based on a 20-year amortization. The interest rate was 3.49% at September 30, 2024. This line is secured by all assets of the Coalition. At September 30, 2024, the Coalition had \$289,244 outstanding on the line of credit, with \$66,276 due within the next year.

SUPPLEMENTARY INFORMATION

METRO DRUG COALITION, INC.
SCHEDULE OF EXPENDITURES OF FEDERAL AND STATE AWARDS
For the Year Ended September 30, 2024

Federal Grantor/Pass-through Grantor/State Grantor	Program/ Cluster Name	Assistance Listing Number	Contract Number	Passed Through to Subrecipients	Expenditures
Federal Awards:					
Pass-through Funding:					
Tennessee Department of Safety and Homeland Security	Tennessee Highway Safety Grant	20.607	Z23THS181	N/A	\$ 52,531
Tennessee Department of Safety and Homeland Security	Tennessee Highway Safety Grant	20.607	Z22THS190	N/A	14,506
Total Program 20.607					<u>67,037</u>
Tennessee Department of Health and Substance Abuse Services	Block Grants for Prevention and Treatment of Substance Abuse	93.959	73278	N/A	149,729
Tennessee Department of Health and Substance Abuse Services	Block Grants for Prevention and Treatment of Substance Abuse	93.959	78128	N/A	20,470
Tennessee Department of Health and Substance Abuse Services	Block Grants for Prevention and Treatment of Substance Abuse	93.959	82389	N/A	8,528
Tennessee Department of Health and Substance Abuse Services	Block Grants for Prevention and Treatment of Substance Abuse	93.959	78127	N/A	77,012
Tennessee Department of Health and Substance Abuse Services	Block Grants for Prevention and Treatment of Substance Abuse	93.959	82379	N/A	76,001
Total Program 93.959					<u>331,740</u>
Substance Abuse and Mental Health Services Administration	Substance Abuse and Mental Health Services Projects of Regional and National Significance	93.243	N/A	N/A	92,271
Tennessee Department of Health and Human Services	Sober Truth on Preventing Underage Drinking Act Grant	93.243	5H79SP081069-02	N/A	39,466
Total Program 93.243					<u>131,737</u>
Tennessee Department of Health and Substance Abuse Services	SOR Community Response	93.788	78005	N/A	39,160
Tennessee Department of Health and Substance Abuse Services	SOR III Coalition	93.788	78005	N/A	219,563
Total Program 93.788					<u>258,723</u>
Total Federal Awards					<u>789,237</u>

(Continued)

METRO DRUG COALITION, INC.

SCHEDULE OF EXPENDITURES OF FEDERAL AND STATE AWARDS
(Continued)

For the Year Ended September 30, 2024

Federal Grantor/Pass-through Grantor/State Grantor	Program/ Cluster Name	CFDA Number	Contract Number	Passed Through to Subrecipients	Expenditures
State Awards:					
Tennessee Department of Children's Services	Adverse Childhood Experiences	N/A	78845	N/A	\$ 178,822
Tennessee Department of Children's Services	Buddies Beamers	N/A	N/A	N/A	10,875
Tennessee Department of Health and Substance Abuse Services	Life Line Grant	N/A	78769	N/A	217,213
Tennessee Department of Health and Substance Abuse Services	Life Line Grant	N/A	82467	N/A	83,953
Tennessee Department of Health and Substance Abuse Services	Faith Based Regional Coordinators	N/A	78444	N/A	51,959
Tennessee Department of Health and Substance Abuse Services	Faith Based Regional Coordinators	N/A	25153	N/A	25,153
Tennessee Department of Health and Substance Abuse Services	Regional Training	N/A	78937	N/A	81,667
Tennessee Department of Health and Substance Abuse Services	Regional Training	N/A	82546	N/A	79,833
Total State Awards					<u>729,475</u>
Total Federal and State Awards					<u>\$ 1,518,712</u>

See independent auditor's report.

METRO DRUG COALITION, INC.

NOTES TO SCHEDULE OF EXPENDITURES OF FEDERAL AND STATE AWARDS

For the Year Ended September 30, 2024

Note A – Basis of Presentation

The accompanying schedule of federal and state awards (the Schedule) includes federal and state award activity of the Metro Drug Coalition, Inc. under programs of the federal and state governments for the year ended September 30, 2024. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. Code of Federal Regulations Part 200, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards (Uniform Guidance).

Note B – Summary of Significant Accounting Policies

- (1) Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance and/or OMB Circular A87, *Cost Principles for State, Local, and Indian Tribal Governments*, wherein certain types of expenditures are not allowable or are limited as to reimbursement.
- (2) Metro Drug Coalition, Inc. has not elected to use the 10 percent *de minimus* indirect cost rate as allowed under the Uniform Guidance.

BROWN JAKE & McDANIEL, PC

**CERTIFIED PUBLIC ACCOUNTANTS
2607 KINGSTON PIKE, SUITE 110
KNOXVILLE, TENNESSEE 37919-3336
865/637-8600 • fax: 865/637-8601
www.bjmpc.com**

JOE L. BROWN, CPA, CGFM, CGMA
FRANK D. McDANIEL, CPA, CGFM, CGMA
TERRY L. MOATS, CPA, CGFM, CGMA
JAMES E. BOOHER, CPA, CGMA
HALEY S. SLAGLE, CPA, CGMA

**MEMBERS
AMERICAN INSTITUTE OF
CERTIFIED PUBLIC ACCOUNTANTS**

**INDEPENDENT AUDITOR'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND
ON COMPLIANCE AND OTHER MATTERS BASED ON AN AUDIT OF FINANCIAL STATEMENTS
PERFORMED IN ACCORDANCE WITH *GOVERNMENT AUDITING STANDARDS***

Board of Directors
Metro Drug Coalition, Inc.
Knoxville, Tennessee

We have audited, in accordance with the auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States, the financial statements of Metro Drug Coalition, Inc. (a nonprofit organization), which comprise the statement of financial position as of September 30, 2024, and the related statements of activities, functional expenses and cash flows for the year then ended, and the related notes to the financial statements, and have issued our report thereon dated August 13, 2025.

Report on Internal Control over Financial Reporting

In planning and performing our audit of the financial statements, we considered Metro Drug Coalition, Inc.'s internal control over financial reporting (internal control) as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of Metro Drug Coalition, Inc.'s internal control. Accordingly, we do not express an opinion on the effectiveness of Metro Drug Coalition, Inc.'s internal control.

A *deficiency in internal control* exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct misstatements on a timely basis. A *material weakness* is a deficiency, or combination of deficiencies, in internal control such that there is a reasonable possibility that a material misstatement of the entity's financial statements will not be prevented, or detected and corrected on a timely basis. A *significant deficiency* is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we identified deficiencies in internal control that we consider to be material weaknesses as items #2024-001 and #2024-003.

Report on Compliance and Other Matters

As part of obtaining reasonable assurance about whether Metro Drug Coalition, Inc.'s financial statements are free of material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts and grant agreements, noncompliance with which could have a direct and material effect on the financial statements. However, providing an opinion on compliance with those provisions was not an objective of our audit and, accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Metro Drug Coalition, Inc.'s Response to Findings

The Coalition's responses to findings identified in our audit are described in the accompanying schedule of findings and questioned costs. The Coalition's responses were not subjected to the auditing procedures applied in the audit of the financial statements and, accordingly, we express no opinion on them.

Purpose of this Report

The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the entity's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the entity's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Brown Lake & McDaniel, PC

Knoxville, Tennessee

August 13, 2025

BROWN JAKE & McDANIEL, PC
CERTIFIED PUBLIC ACCOUNTANTS
2607 KINGSTON PIKE, SUITE 110
KNOXVILLE, TENNESSEE 37919-3336
865/637-8600 • fax: 865/637-8601
www.bjmpc.com

JOE L. BROWN, CPA, CGFM, CGMA
FRANK D. McDANIEL, CPA, CGFM, CGMA
TERRY L. MOATS, CPA, CGFM, CGMA
JAMES E. BOOHER, CPA, CGMA
HALEY S. SLAGLE, CPA, CGMA

MEMBERS
AMERICAN INSTITUTE OF
CERTIFIED PUBLIC ACCOUNTANTS

**INDEPENDENT AUDITOR'S REPORT ON COMPLIANCE FOR EACH MAJOR PROGRAM AND ON
INTERNAL CONTROL OVER COMPLIANCE REQUIRED BY THE UNIFORM GUIDANCE**

Board of Directors
Metro Drug Coalition, Inc.
Knoxville, Tennessee

Report on Compliance for Each Major Federal Program

Opinion on Each Major Federal Program

We have audited the Metro Drug Coalition, Inc.'s (the Coalition) compliance with the types of compliance requirements identified as subject to audit in the *OMB Compliance Supplement* that could have a direct and material effect on each of the Coalition's major federal programs for the year ended September 30, 2024. The Coalition's major federal programs are identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Coalition complied, in all material respects, with the types of compliance requirements referred to above that could have a direct and material effect on each of its major federal programs for the year ended September 30, 2024.

Basis for Opinion on Each Major Federal Program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America; the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States; and the audit requirements of Title 2 U.S. Code of Federal Regulations Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Coalition and to meet our other ethical responsibilities, in accordance with relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for each major federal program. Our audit does not provide a legal determination of the Coalition's compliance with the compliance requirements referred to above.

Responsibilities of Management for Compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of

laws, statutes, regulations, rules, and provisions of contracts or grant agreements applicable to the Coalition's federal programs.

Auditor's Responsibilities for the Audit of Compliance

Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Coalition's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with generally accepted auditing standards, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Coalition's compliance with the requirements of each major federal program as a whole.

In performing an audit in accordance with generally accepted auditing standards, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Coalition's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the Coalition's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the Coalition's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on Internal Control Over Compliance

A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. *A material weakness in internal control over compliance* is a deficiency, or combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. *A significant deficiency in internal control over compliance* is a deficiency, or a combination of deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charges with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be a material weakness or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal

control over compliance that we consider to be material weaknesses, as defined above. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this report on internal control over compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Brown Lake + McDaniel, PC
CERTIFIED PUBLIC ACCOUNTANTS

Knoxville, Tennessee
August 13, 2025

INDEPENDENT AUDITOR'S REPORT ON COMPLIANCE FOR EACH MAJOR PROGRAM AND ON
INTERNAL CONTROL OVER COMPLIANCE REQUIRED BY THE UNIFORM GUIDANCE

ACCOMPANYING SCHEDULE OF FINDINGS AND QUESTIONED COSTS

I. SUMMARY OF AUDITOR'S RESULTS

- A. An unmodified opinion was issued on the basic financial statements of Metro Drug Coalition, Inc. for the year ended September 30, 2024.
- B. Internal control over financial reporting:
Material weakness(es) identified? yes no
Significant deficiency(ies) identified that are not considered to be material weakness(es)? yes none reported
- C. Our audit disclosed no instances of noncompliance considered by us to be material to the financial statements.
- D. Internal control over major programs:
Material weakness(es) identified? yes no
Significant deficiency(ies) identified that are not considered to be material weakness(es)? yes none reported
- E. An unmodified opinion was issued for compliance for Metro Drug Coalition, Inc.'s major programs.
- F. The audit disclosed no audit findings requiring reporting under Section .510(a).
- G. We identified the following major federal assistance programs:
93.959 Block Grants for Substance Use Prevention, Treatment, and Recovery Services
- H. The threshold for distinguishing between Type A and Type B programs was \$750,000.
- I. The auditee was determined to be a high risk auditee.

II. SUMMARY OF FINDINGS REPORTED AT THE FINANCIAL STATEMENT LEVEL

Finding 2024-001: Material Auditor-Proposed Adjusting Entries

Condition: During our audit, we proposed significant adjustments to various asset, liability, and equity accounts, so the Coalition's financial statements would conform to generally accepted accounting principles.

Criteria: Before the auditors receive the financial records to begin audit procedures, all asset, liability, and equity accounts should be reconciled, adjusted and/or recorded in the financial records.

II. SUMMARY OF FINDINGS REPORTED AT THE FINANCIAL STATEMENT LEVEL (Continued)

Finding 2024-001: Material Auditor-Proposed Adjusting Entries (Continued)

Effect: Before auditor-proposed adjustments were posted, certain asset and liability accounts were materially misstated.

Recommendation: We recommend all asset, liability, and equity accounts be reconciled, adjusted, and/or recorded to the financial records before audit procedures begin.

Management's Response: We concur with the finding.

Finding 2024-002: Allocation Plan Approval

Condition: During our audit, we tested various expenses for allocation among programs/functions and noted that the Coalition was not following an approved allocation plan per Board policy.

Criteria: Allocation plan for expenditures should be approved by the State per Board policy.

Cause: Records of allocation plan approval were not kept by the Coalition and updated throughout the year as new funding sources are received and as other funding sources expire.

Effect: The Coalition did not allocate expenditures based on an approved state allocation.

Recommendation: We recommend the Coalition obtain expenditure allocation plan approval prior to start of new fiscal year and update it as necessary throughout the year.

Management's Response: We concur with the finding.

Finding 2024-003: Cash Disbursements

Condition: We noted during our audit, instances of invoices not approved for payment. We also noted the client was not retaining the ACH bank payment documentation, was not following the bid or quote policy, and there were numerous instances of missing supporting documentation.

Criteria: Approval, ACH documentation, bids and quotes, and invoices or supporting documentation should be retained to verify that all of the Coalition's purchasing policies are adhered to, and expenditures have proper supporting documentation to prove they are for a valid Coalition business purpose.

Cause: Failure to follow the Coalition's policy allowed purchases to be made without proper approval, without obtaining required bids and quotes, and not maintaining proper supporting documentation.

Effect: The Coalition made purchases without following their purchasing policy.

Recommendation: The Coalition should abide by their purchasing policy. Steps should also be taken to ensure that employees follow the purchasing policy so all expenditures are properly documented, approved, and bids or quotes obtained when required.

Management's Response: We concur with the finding.

III. SUMMARY OF FINDINGS AND QUESTIONED COSTS FOR FEDERAL AWARDS

None

METROPOLITAN DRUG COALITION, INC.
SUMMARY SCHEDULE OF PRIOR AUDIT FINDINGS

Original Finding Number	Prior Year Finding Number	Finding Title	Status	Current Year Finding Number
2023-001	2023-001	Material Auditor – Proposed Adjusting Entries	Repeated	2024-001
2023-002	2023-002	Allocation Plan Approval	Repeated	2024-002



Executive Committee

Barbara Shipley, President
Elizabeth Sherrod, Vice President
Sam French, Treasurer
Maha Krishnamurthy, Immediate Past President

At-Large Members

Sheriff Tom Spangler, At Large
Gen. Charme Allen, At Large
Dan Sherrod, At Large
Jim Lapinska, At Large

Board At-Large

Tanisha Baker
Commissioner Richie Beeler
Eric Botts
State Rep. Michele Carringer
Lara Fleming
Betsy Henderson
Beth Hoffer
Hon. Tim Irwin
Mayor Glenn Jacobs
Mayor Indya Kincannon
P.D. Eric Lutton
George Massengill
Chuck Morris
Chief Paul Noel
Kevin Parton
Jon Rysewyk
Seema Singh
April Snell
Janet Testerman
Matt Tillery
Jennifer Tourville
Zach Wishart

Management's Corrective Action Plan

Finding #2024-001: Material Auditor-Proposed Adjusting Entries

Response and Corrective Action Plan Prepared by: Tony Pierce, Director of Finance
Person Responsible for Implementing the Corrective Action: Tony Pierce, Director of Finance
Anticipated Date of Corrective Action: Immediate and Continuous
Repeat Finding: Yes

Planned Corrective Action: Finance will review, reconcile and adjust all general ledger accounts prior to submitting financial records for audit review. All prior year adjusting entries will be reviewed and recorded by fiscal year end to prevent duplication or reoccurrence of auditor-proposed entries. In addition, management has been implementing regular monthly close and reconciliation processes since the findings were identified.

Finding #2024-002: Allocation Plan Approval

Response and Corrective Action Plan Prepared by: Tony Pierce, Director of Finance
Person Responsible for Implementing the Corrective Action: Tony Pierce, Director of Finance
Anticipated Date of Corrective Action: Immediate
Repeat Finding: Yes

Planned Corrective Action: The cost allocation plan is currently being updated to reflect the new State fiscal year and new grant funding. Once completed, the allocation plan will be sent to the appropriate State agency for review.

Finding #2024-003: Cash Disbursements

Response and Corrective Action Plan Prepared by: Tony Pierce, Director of Finance
Person Responsible for Implementing the Corrective Action: Tony Pierce, Director of Finance
Anticipated Date of Corrective Action: Immediate and Continuous
Repeat Finding: No

Planned Corrective Action: Metro Drug Coalition will retain all supporting documentation for cash disbursements, including but not limited to; check stubs, online payment receipts, credit card receipts and ACH payment summaries. To ensure no lost banking information, Finance will print and retain all banking payment information by date and vendor.

The Director of Finance will ensure all appropriate backup documentation is included with each disbursement, such as invoice, approvals, and payment confirmation. Files will be kept easily accessible for future audits.

Webster Bailey

Executive Director